Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 4/20 | 0.68 |
| ▸ | LIPE | Q05469 | 2/20 | 0.39 |
| ▸ | HCRTR1 | O43613 | 8/20 | 0.39 |
| ▸ | HCRTR2 | O43614 | 8/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13435176 | 0.93 | HSD11B1 (0.59) | HSD11B1LIPEHCRTR1HCRTR2CYP3A4 | |
| SCHEMBL13435168 | 0.90 | HSD11B1 (0.68) | HSD11B1HCRTR1HCRTR2CYP3A4 | |
| SCHEMBL13435186 | 0.84 | HSD11B1 (0.76) | HSD11B1EPHX2 | |
| SCHEMBL3427426 | 0.83 | HSD11B1 (0.78) | HSD11B1ALDH1A1TSHR | |
| SCHEMBL13435184 | 0.82 | HSD11B1 (0.76) | HSD11B1ALDH1A1TSHR | |
| SCHEMBL13435191 | 0.81 | HSD11B1 (1.00) | HSD11B1ALDH1A1 | |
| SCHEMBL13435177 | 0.79 | HSD11B1 (0.64) | HSD11B1 | |
| SCHEMBL3427613 | 0.76 | HSD11B1 (0.64) | HSD11B1ALDH1A1TSHR | |
| SCHEMBL3421958 | 0.76 | HSD11B1 (0.70) | HSD11B1ALDH1A1HRH3 | |
| SCHEMBL13435179 | 0.75 | HSD11B1 (0.59) | HSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7687644-B2 | Adamantyl pyrrolidin-2-one derivatives as 11-beta hydroxysteroid dehydrogenase inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2010-03-30 | — | — | US | disclosed |
| US-7687644-B2 | Adamantyl pyrrolidin-2-one derivatives as 11-beta hydroxysteroid dehydrogenase inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2010-03-30 | — | — | US | disclosed |
| US-20070287743-A1 | Adamantyl Pyrrolidin-2-One Derivatives as 11-Beta Hydroxtsteroid Dehydrogenase Inhibitors | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-12-13 | — | — | US | disclosed |
| US-20070287743-A1 | Adamantyl Pyrrolidin-2-One Derivatives as 11-Beta Hydroxtsteroid Dehydrogenase Inhibitors | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-12-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070287743-A1 | Adamantyl Pyrrolidin-2-One Derivatives as 11-Beta Hydroxtsteroid Dehydrogenase Inhibitors | HSD11B1, HSD11B2, HSDL2 | HSD11B1 1/4885LIPE 3008/4885HCRTR1 1505/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.